AU2002230993B2 - Particles for inhalation having sustained release properties - Google Patents

Particles for inhalation having sustained release properties Download PDF

Info

Publication number
AU2002230993B2
AU2002230993B2 AU2002230993A AU2002230993A AU2002230993B2 AU 2002230993 B2 AU2002230993 B2 AU 2002230993B2 AU 2002230993 A AU2002230993 A AU 2002230993A AU 2002230993 A AU2002230993 A AU 2002230993A AU 2002230993 B2 AU2002230993 B2 AU 2002230993B2
Authority
AU
Australia
Prior art keywords
glycero
particles
lipid
agent
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002230993A
Other languages
English (en)
Other versions
AU2002230993A1 (en
Inventor
Sujit K. Basu
David A. Edwards
Katharina Elbert
Jeffrey S. Hrkach
Michael Lipp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Priority to AU2002350606A priority Critical patent/AU2002350606B2/en
Publication of AU2002230993A1 publication Critical patent/AU2002230993A1/en
Application granted granted Critical
Publication of AU2002230993B2 publication Critical patent/AU2002230993B2/en
Assigned to ALKERMES, INC. reassignment ALKERMES, INC. Request for Assignment Assignors: ADVANCED INHALATION RESEARCH, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002230993A 2000-12-29 2001-12-18 Particles for inhalation having sustained release properties Ceased AU2002230993B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002350606A AU2002350606B2 (en) 2000-12-29 2002-06-24 Particles for inhalation having rapid release properties

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75210900A 2000-12-29 2000-12-29
US09/752,109 2000-12-29
PCT/US2001/048956 WO2002053190A2 (en) 2000-12-29 2001-12-18 Particles for inhalation having sustained release properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2002350606A Division AU2002350606B2 (en) 2000-12-29 2002-06-24 Particles for inhalation having rapid release properties

Publications (2)

Publication Number Publication Date
AU2002230993A1 AU2002230993A1 (en) 2003-01-23
AU2002230993B2 true AU2002230993B2 (en) 2006-02-02

Family

ID=25024911

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002230993A Ceased AU2002230993B2 (en) 2000-12-29 2001-12-18 Particles for inhalation having sustained release properties

Country Status (6)

Country Link
US (2) US7048908B2 (https=)
EP (1) EP1345629A2 (https=)
JP (2) JP2005504715A (https=)
AU (1) AU2002230993B2 (https=)
CA (1) CA2433335C (https=)
WO (1) WO2002053190A2 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7678364B2 (en) * 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
WO2002053190A2 (en) * 2000-12-29 2002-07-11 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
EP1575976A4 (en) 2001-11-02 2006-08-23 Insert Therapeutics Inc METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
CN1607941A (zh) * 2001-11-19 2005-04-20 贝克顿迪肯森公司 粒状药物组合物
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
BRPI0414907A (pt) * 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
CA2618710A1 (en) * 2005-08-11 2007-02-22 David Edwards Methods and compositions for dried cellular forms
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
EP2202239A1 (en) 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAI inhibition of influenza virus replication
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US7846908B2 (en) 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
EP2392583A1 (en) 2006-05-19 2011-12-07 Alnylam Europe AG. RNAi modulation of Aha and therapeutic uses thereof
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
CN102037123A (zh) 2008-04-04 2011-04-27 卡兰多制药股份有限公司 Epas1抑制剂的组合物和用途
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
CN107596518B (zh) * 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
WO2014070687A2 (en) 2012-10-29 2014-05-08 Molecular Transfer, Inc. Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
PL2970389T3 (pl) * 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2016067252A1 (en) 2014-10-31 2016-05-06 Glaxosmithkline Intellectual Property Development Limited Powder formulation
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
AU2016287582B2 (en) 2015-07-02 2020-03-12 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
US20180303753A1 (en) * 2015-09-09 2018-10-25 Keith Try Ung Targeted delivery of spray-dried formulations to the lungs
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
US10067160B2 (en) 2016-11-16 2018-09-04 CBN Nano Technologies, Inc. Sequential tip systems and methods for positionally controlled chemistry
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
WO2018200425A1 (en) 2017-04-24 2018-11-01 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
EP3829719B1 (en) 2018-07-27 2025-04-02 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
CN113286793B (zh) 2018-09-10 2024-04-05 共结晶制药公司 吡咯并吡嗪和吡啶并三嗪类流感病毒复制抑制剂
KR102890706B1 (ko) 2018-10-17 2025-11-24 코크리스탈 파마, 아이엔씨. 인플루엔자 바이러스 복제 억제제의 조합물
EP3887355A1 (en) 2018-11-26 2021-10-06 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
WO2021188620A1 (en) 2020-03-17 2021-09-23 Cocrystal Pharma Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
CN115698035A (zh) 2020-04-10 2023-02-03 共晶制药公司 诺如病毒及冠状病毒复制的抑制剂
EP4291306A1 (en) 2021-02-09 2023-12-20 University of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
JP2024530920A (ja) 2021-08-03 2024-08-27 コクリスタル ファーマ，インコーポレイテッド コロナウイルスに対する阻害剤
WO2023198757A1 (en) 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040963A1 (en) * 1995-06-07 1996-12-19 Megabios Corporation Cationic lipid:dna complexes for gene targeting
WO1996041873A1 (en) * 1995-06-09 1996-12-27 The Regents Of The University Of California Dry powder formulations of polynucleotide complexes
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1998051278A2 (en) * 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533065A (en) 1947-03-08 1950-12-05 George V Taplin Micropulverized therapeutic agents
US2470296A (en) 1948-04-30 1949-05-17 Abbott Lab Inhalator
US2992645A (en) 1958-05-06 1961-07-18 Benger Lab Ltd Disperser for powders
US3957965A (en) 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
AU439432B2 (en) 1968-11-28 1972-08-15 Dulux Australia Ltd Polymer and coating composition
US4173488A (en) 1968-12-23 1979-11-06 Champion International Corporation Oil-in-water emulsions containing hydropholeic starch
US3781230A (en) 1968-12-23 1973-12-25 Champion Int Corp Microcapsular opacifier system
GB1410588A (en) 1971-08-10 1975-10-22 Fisons Ltd Composition
US4089800A (en) 1975-04-04 1978-05-16 Ppg Industries, Inc. Method of preparing microcapsules
US4161516A (en) 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4743545A (en) 1984-08-09 1988-05-10 Torobin Leonard B Hollow porous microspheres containing biocatalyst
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4276885A (en) 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US5260306A (en) 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
EP0072046B1 (en) 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
DE3141641A1 (de) 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
US4480041A (en) 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4572203A (en) 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4865789A (en) 1983-11-14 1989-09-12 Akzo Nv Method for making porous structures
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
AU565354B2 (en) 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
CA1215922A (en) 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4679555A (en) 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
EP0248051A1 (en) 1985-11-29 1987-12-09 FISONS plc Pharmaceutical composition including sodium cromoglycate
GB8601100D0 (en) 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US5160745A (en) 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
US4741872A (en) 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
EP0257915B1 (en) 1986-08-11 1993-03-10 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
DE3637926C1 (de) 1986-11-05 1987-11-26 Schering Ag Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen
JPS63122620A (ja) 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US4897256A (en) 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5204113A (en) 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8712176D0 (en) 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
US5069936A (en) 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US4855144A (en) 1987-10-23 1989-08-08 Advanced Polymer Systems Synthetic melanin aggregates
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
AU3073789A (en) 1988-03-31 1989-10-05 Abbott Laboratories Drug delivery using pulmonary surfactant to facilitate absorption
US5064650A (en) 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US4917119A (en) 1988-11-30 1990-04-17 R. J. Reynolds Tobacco Company Drug delivery article
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US4976968A (en) 1989-02-24 1990-12-11 Clinical Technologies Associates, Inc. Anhydrous delivery systems for pharmacological agents
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
KR920703016A (ko) 1989-10-03 1992-12-17 데이비드 더블유, 라이트 용해성의 마이크로다공성 하이드로겔 입자 및 그것의 제조방법
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
WO1991006286A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Method for producing protein microspheres
US5352435A (en) 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5334381A (en) 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
GB9003821D0 (en) 1990-02-20 1990-04-18 Danbiosyst Uk Diagnostic aid
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
SE9002017D0 (sv) 1990-06-06 1990-06-06 Kabivitrum Ab Process for manufacture of matrices
CA2085884C (en) 1990-06-29 2001-12-04 Asit Somani Pressurized hydrofluorocarbon aerosol compositions
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
DK0586524T3 (https=) 1991-06-03 1997-05-20 Nycomed Imaging As
ZA924164B (en) 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
US5409688A (en) 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
EP0617610B1 (en) 1991-12-18 1997-03-19 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
US5169871A (en) 1991-12-19 1992-12-08 Hoechst Celanese Corp. Highly porous compressible polymeric powders
ES2181691T5 (es) 1992-06-11 2007-10-01 Alkermes Controlled Therapeutics, Inc. Sistema de distribucion de proteina eritropoyetina.
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
ES2179831T3 (es) 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
GB9221329D0 (en) 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
US5698721A (en) 1992-12-17 1997-12-16 Megabios Corporation Catonic amphiphiles
EP0680341B1 (en) 1993-01-25 2001-05-09 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
GB9301629D0 (en) 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
US5456917A (en) 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
ES2152990T3 (es) 1993-09-09 2001-02-16 Schering Ag Principios activos y microparticulas que contienen gases.
SK283569B6 (sk) 1993-10-01 2003-09-11 Astra Aktiebolag Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
NZ281112A (en) 1994-03-07 1998-04-27 Inhale Therapeutic Syst Powdered insulin delivered as an aerosol
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
PL319600A1 (en) 1994-09-29 1997-08-18 Andaris Ltd Spray-dried microparticles as therapeutic carriers
GB9423419D0 (en) 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
JP4320054B2 (ja) * 1996-08-13 2009-08-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ポリヌクレオチド送達のための組成物および方法
JP2001502666A (ja) * 1996-09-12 2001-02-27 ジェネメディシン，インコーポレイテッド 肺遺伝子送達のための組成物および方法
US6077543A (en) 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
CN1169520C (zh) 1997-09-29 2004-10-06 耐科塔医药公司 多孔微粒及其使用方法
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
WO2002053190A2 (en) * 2000-12-29 2002-07-11 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US20030125236A1 (en) * 2000-12-29 2003-07-03 Advenced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040963A1 (en) * 1995-06-07 1996-12-19 Megabios Corporation Cationic lipid:dna complexes for gene targeting
WO1996041873A1 (en) * 1995-06-09 1996-12-27 The Regents Of The University Of California Dry powder formulations of polynucleotide complexes
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1998051278A2 (en) * 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles

Also Published As

Publication number Publication date
US20030118513A1 (en) 2003-06-26
JP2006249099A (ja) 2006-09-21
EP1345629A2 (en) 2003-09-24
CA2433335A1 (en) 2002-07-11
US7048908B2 (en) 2006-05-23
US20080039366A1 (en) 2008-02-14
JP2005504715A (ja) 2005-02-17
WO2002053190A2 (en) 2002-07-11
CA2433335C (en) 2010-04-20
WO2002053190A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
AU2002230993B2 (en) Particles for inhalation having sustained release properties
US7628977B2 (en) Particles for inhalation having sustained release properties
AU2002230993A1 (en) Particles for inhalation having sustained release properties
AU2002242253B2 (en) Modulation of release from dry powder formulations
US7052678B2 (en) Particles for inhalation having sustained release properties
AU764738B2 (en) Use of simple amino acids to form porous particles
US7678364B2 (en) Particles for inhalation having sustained release properties
US20020141946A1 (en) Particles for inhalation having rapid release properties
US20040018243A1 (en) Modulation of release from dry powder formulations
AU2002242253A1 (en) Modulation of release from dry powder formulations
US7252840B1 (en) Use of simple amino acids to form porous particles
EP1797902A2 (en) Particles for inhalation having sustained release properties
HK1102494A (en) Particles for inhalation having sustained release properties
AU2002350606A1 (en) Particles for inhalation having rapid release properties

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALKERMES, INC.

Free format text: FORMER OWNER WAS: ADVANCED INHALATION RESEARCH, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired